How affordable are targeted therapies in non-small cell lung cancer?
As the treatment of non-small cell lung cancer (NSCLC) evolves to include more targeted therapies, costs of treatment have increased significantly. Advances in NSCLC treatment include longer survival duration, and in some cases, better progression-free survival and quality of life, and the potential for decreased toxicity. Through pharmacoeconomic analyses, payors seek to value the improvements in outcomes from novel therapies, and relate these improvements to their costs. In NSCLC, three categories of novel agents have been introduced into clinical practice: (1) agents targeting the epidermal growth factor receptor (EGFR); (2) agents targeting the vascular endothelial growth factor (VEGF) and (3) novel chemotherapy agents, specifically pemetrexed. Here we review published economic analyses for these agents in lung cancer, and their potential impact on treatment decisions.
Division of Medical Oncology, Princess Margaret Hospital, Toronto, ON, Canada.
Linda E
LE
Coate
Natasha B
NB
Leighl
D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000191:economics* / Q000628:therapy; D006801:Humans; D008175:Lung Neoplasms / Q000191:economics* / Q000628:therapy; D057285:Precision Medicine
D000970:Antineoplastic Agents
N Engl J Med. 2006 Dec 14;355(24):2542-50
17167137
Curr Med Res Opin. 2007 Jul;23(7):1509-15
17559745
Pharmacoeconomics. 2006;24(7):651-9
16802841
J Clin Oncol. 2010 Feb 10;28(5):744-52
20038723
N Engl J Med. 2010 Jun 24;362(25):2380-8
20573926
J Clin Oncol. 2009 Sep 10;27(26):4247-53
19667264
J Manag Care Pharm. 2006 Jul-Aug;12(6):472-8
16925455
Nat Rev Drug Discov. 2010 Jun;9(6):427-8
20514063
J Clin Oncol. 2000 May;18(10):2095-103
10811675
Oncologist. 2006 Feb;11(2):90-5
16476830
Lancet. 2009 Oct 24;374(9699):1432-40
19767093
Lancet. 2009 May 2;373(9674):1525-31
19410716
J Clin Oncol. 2010 Feb 20;28(6):911-7
20100966
J Natl Cancer Inst. 2009 Aug 5;101(15):1044-8
19564563
N Engl J Med. 2005 Jul 14;353(2):123-32
16014882
Pharmacoeconomics. 2005;23(11):1155-66
16277550
N Engl J Med. 2009 Sep 3;361(10):947-57
19692680
Pharmacoeconomics. 2010;28(1):75-92
20014878
Lancet Oncol. 2009 Nov;10(11):1031-2
19891055
J Clin Oncol. 2009 Jul 10;27(20):3277-83
19470938
Lung Cancer. 2002 Nov;38 Suppl 2:S21-8
12431825
Lung Cancer. 2006 Jan;51(1):137-8
16324767
Pharmacoeconomics. 2004;22(9):581-9
15209527
BMC Cancer. 2010 Jan 29;10:26
20113499
Am J Manag Care. 2008 May;14(5):297-306
18471034
Health Technol Assess. 2010 May;14 Suppl 1:47-53
20507803
J Clin Oncol. 2009 Mar 10;27(8):1227-34
19188680
J Clin Oncol. 2008 Jul 20;26(21):3543-51
18506025
Lung Cancer. 2006 Jan;51(1):115-21
16188343
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
J Natl Cancer Inst. 2010 Mar 3;102(5):298-306
20160168
Lancet. 2008 Nov 22;372(9652):1809-18
19027483
Ann Oncol. 2011 Aug;22(8):1805-11
21273345
J Clin Oncol. 2004 May 1;22(9):1589-97
15117980